The utilization of nanoprobes enables the concurrent administration of an immune checkpoint inhibitor (αPDL1) and imaging probe to the tumor area, facilitating timely monitoring of time‐sensitive granzyme B activity as a direct method for early assessment of immunotherapy efficacy [82]. This evidence concerns the gene GZMB and neoplasm.